Skip to main content
Remuscularizing the Failing Human Heart.
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
Corporate Vectors of Chronic Disease - Using Internal Industry Documents to Craft Counterstrategies.
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.
Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk.
Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.
Oral Infigratinib Therapy in Children with Achondroplasia.
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Implications of Race Adjustment in Lung-Function Equations.